Treatment for severe high blood pressure using targeted artery blockage

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the safety and effectiveness of superselective adrenal arterial embolization (SAAE) in patients suffering from primary refractory hypertension, which is high blood pressure that does not respond to standard treatments. It is a single-center, open-label, self-controlled, single-arm, prospective study involving patients who have been on multiple antihypertensive medications without success. After the SAAE procedure, participants will be monitored for 8 weeks to assess the outcomes of the treatment.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age \> 18 years, no gender restrictions;
* Primary refractory hypertension: Taking three antihypertensive drugs, including a - diuretic, with an average office systolic blood pressure ≥150 mmHg measured three times;
* Duration of hypertension greater than 6 months;
* Standing plasma aldosterone and renin activity not below the lower limit of the unit's reference range;
* Signed informed consent form.

Exclusion Criteria:

* Morning cortisol level \< 4.3 µg/dL; estimated glomerular filtration rate (eGFR) \< 45 mL/min/1.73 m²; serum potassium level \> 5.5 mmol/L;
* Type 1 diabetes, uncontrolled hyperthyroidism, malignant arrhythmias, malignant tumors, decompensated heart failure, severe liver dysfunction, severe hematological diseases, severe obstructive sleep apnea syndrome, history of myocardial infarction, syncope, cerebral hemorrhage, or cerebral infarction within the past 3 months;
* Pregnant women or those planning to conceive within the next year;
* Presence of other severe organic diseases that would make the patient unable to tolerate superselective adrenal arterial embolization;
* Adrenal mass with a diameter exceeding 2 cm;
* Severe allergy to contrast agents;
* Patients enrolled or planning to participate in other clinical studies that could impact the results of this study.

Where it's running

• The Second Affiliated Hospital of Nanchang University
  Nanchang, China Recruiting

Study contacts

• Principal investigator: Yifei Dong, Doctor — Second Affiliated Hospital of Nanchang University
• Study coordinator: Yifei the second affiliated hospital of Nanchang university, Doctor
• Email: yf_dong66@126.com
• Phone: (0791)86209562

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Isometric wall squat exercise to lower blood pressure in adults with hypertension

  We’re testing whether doing isometric wall squats at home for 12 weeks can help lower 24-hour blood pressure in adults with essential hypertension.

  Recruiting Korea University Guro Hospital · Seoul, Seoul · NCT07868822

• MWX401 Injection in healthy adults and people with mild hypertension

  This early Phase 1 study tests a single subcutaneous dose of MWX401 to see if it's safe and tolerable in healthy Chinese adults and in adults with mild high blood pressure.

  Recruiting Phase 1 Shanghai Minwei Biotechnology Co., Ltd · Nanjing, Jiangsu · NCT07803835

• Single-use intravascular ultrasound (IVUS) ablation for primary hypertension

  This will test whether a single-use intravascular ultrasound ablation device can safely lower blood pressure in adults with primary (essential) hypertension who are on a standardized ARB/CCB-based medication regimen.

  Recruiting at 15 sites Lepu Medical Technology (Beijing) Co., Ltd. · Beijing, Beijing Municipality and 17 other locations · NCT07051811

• Study of childhood high blood pressure and its genetic factors

  This study is trying to find out how genes affect high blood pressure in kids by looking at their health over several years to help create better treatments.

  Recruiting National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT06778239

• CKD-202A (sacubitril/valsartan) for adults with high blood pressure

  This trial will test whether CKD-202A (sacubitril/valsartan) controls blood pressure safely in adults with essential hypertension compared with valsartan.

  Recruiting Phase 3 Chong Kun Dang Pharmaceutical · Wŏnju · NCT06643819

• Evaluating the effects of two medications for high blood pressure

  This study is testing whether a combination of two new medications can help people with high blood pressure feel better and stay safe.

  Recruiting Phase 3 Addpharma Inc. · Seoul · NCT06441630

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.